Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  
                                 
 

Journal of Developing Drugs


Open Access
 
 
 
ISSN: 2329-6631
 
 
 
home » journals » healthcare-spending-blessing-or-curse-2329-6631 Rss Feed Rss Feed
 
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
 
 
Editorial Open Access
 
Healthcare Spending: Blessing or Curse
University of the Pacific, USA Peter Hilsenrath* and University of the Pacific, USA Katrina Fischer
 
Corresponding Author : Peter Hilsenrath
Professor, University of the Pacific, USA
Tel: 209-946-2642
E-mail: philsenrath@PACIFIC.EDU
 
Received June 24, 2013; Accepted June 24, 2013; Published June 28, 2013
 
Citation: Hilsenrath P, Fischer K (2013) Healthcare Spending: Blessing or Curse. J Develop Drugs 2:e125. doi: 10.4172/2329-6631.1000e125
 
Copyright: © 2013 Hilsenrath P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Related article at
DownloadPubmed DownloadScholar Google
 
 
Can’t Make Head or Tail of it
 
Readers of the Journal of Developing Drugs are well schooled in natural sciences. But few are likely to have time or inclination to dwell in the world of economic affairs even though the course of scientific discovery is as much influenced by economic events as it shapes the unfolding world of future technology. Technology is an endogenous variable in neoclassical economics. Its interaction with the economy is not fully understood but is known to be the one of the most, if not the most, important factor driving long term economic development, jobs and prosperity. New technology can quickly reshape the economy. Take for example the automobile industry. It grew from virtually nothing to a substantial proportion of the economy by mid-century if one includes related industries such as tyres, petroleum and repair. Or consider development of internet, which accounted for 21 percent of GDP growth over the past five years [1]. National health expenditures (NHE) are currently 18 percent of the economy but are expected to reach 25 percent by 2037 [2]. Is this growth in the health sector a blessing or a curse?
 
In the United States retail pharmacy expenditures increased from 4.7 to 9.8 percent of NHE from 1980 to 2010. Much of this growth is associated with the spread of health insurance for pharmaceuticals. The development of health insurance in the United States was originally focused on hospital and physician services. Insurance coverage for drugs evolved later, first in the private sector and then in the public sector. Coverage for retail prescription drugs for Medicare, primarily for those over 65, was implemented as recently as 2006. In addition, generous tax provisions exist in the United States shielding compensation in the form of health insurance from taxation. This further encourages health insurance coverage and medical expenditures including for prescription drugs.
 
There can be little doubt about the importance of new drugs in recent decades especially in the academic community. The 5 year averages of U.S. academic patents by technology area are shown below, illustrating large increases in biotechnology and pharmaceutical patents in the latter part of the 1990’s that has been largely sustained, at least through the first decade of the 21st century. The increased availability of new pharmaceuticals and treatment options, particularly biologics, will hopefully lead to improved patient care and prolonged life (Figure 1).
 
There is a concurrent, less auspicious perspective focused on how beneficial these developments have been for the pharmaceutical and pharmacy sectors. Health in the United States, as measured by life expectancy and infant mortality, is weak in comparison to other developed countries. Health spending should lead to better health and one would expect an advanced economy such as the US to excel. Yet the World Health Organization (WHO) found that the United States fared poorly compared to other countries in the efficiency of its health spending [3]. Figure 1 illustrates relatively high US spending with a trend line plotting the relationship between per capita income and the share of GDP allocated to healthcare using primarily OECD data. The United States clearly stands out.
 
The US health sector is fragmented and uncoordinated. A key source of inefficiency is the wedge between the price consumers pay and the cost of production. Economists refer to the moral hazard of overconsumption when someone else bears the costs. In the longer run moral hazard leads to incentives for new technologies that drive up costs, rather than reduce them (Figure 2).
 
How can these two different narratives be reconciled? The two perspectives are not mutually exclusive. Both have veracity. An inefficient healthcare sector can generate many jobs and profound benefits. But inefficiency initially slows growth, eventually reaching a tradeoff: reduce spending or reduce our standard of living in non-healthcare sectors. Higher health benefit costs are already an important variable in the stagnation of median wages and slowdowns in growth in the United States.
 
What is to be Done?
 
In 1902 Vladimir Lenin published “What is to be done?” The ambitious revolutionary called for an end to the vacillation of the progressive movement and demanded decisive action about unacceptable social conditions of his day. Although the Bolsheviks certainly provided the Russian public decisive action, many decisions were wrong. Health care in some respects faces analogous circumstances. Important decisions must be made about what is affordable, and more importantly what is beyond affordability. In cases where the public is over-insured, markets can be used to address these decisions; consumers will vote with their pocket books. For more expensive care, decisions will be determined by insurers. But these are essentially social decisions and the public sector will need to show real leadership. A great risk is that we throw the baby out with the bathwater. New technology generating large social benefits well in excess of cost should not be stifled, as long as decisions are aided with sound cost-effectiveness analyses. Such analyses are found in many countries, the most well-known being the United Kingdom with its National Institute for Care and Health Excellence (NICE). Industry interests in the United States have fiercely resisted reliance on cost effectiveness analyses for insurance coverage decisions but as a compromise, the US has supported comparative effectiveness analyses with emphasis on outcomes rather than costs [4]. The same spirit of improving allocative efficiency, that is allocating resources across the economy to where they generate the greatest benefit, is finding its way to decisions about research funding. Research should be directed to topics that hold the greatest promise for the greatest good. Of course, research funding has been scarce for a long time and subject to scrutiny. But this scrutiny has historically been left to the scientific community. In some European countries, this process is becoming more pluralistic with input from outside the scientific community. The United States can be expected to follow suit.
 
Another important element to reforming R&D funding is a new focus on productive efficiency. Productive efficiency describes producing a product for a given quantity and quality at the lowest cost possible. This kind of efficiency is well understood by managers throughout the American economy, except in the health sector (with some incipient signs of change not withstanding). Industrial research commonly seeks lower cost and higher quality products, yet this culture is alien to most academic health science centers in the United States. How many academic health researchers look for new ways to provide less costly care and products? Game changing innovation more commonly comes from the private sector with little, if any support from established players in health. This state of affairs is not likely to persist indefinitely and research funding can be expected to lend greater support to gains in productive efficiency.
 
References
 




 


 View 

 Download    pdf version of this article



Figures at a glance

 
Figure 1  Figure 2
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Adverse Drug Reactions
Disc Antigen – Antibody Reaction
Disc Anvisa Drug Safety Regulations
Disc Biochemical Metabolism
Disc Clinical Pharmacoepidemiological Trails
Disc Cytochrome 450 Drug Metabolism
Disc Cytotoxicity
Disc Detoxification
Disc Drug Delivery
Disc Drug Delivery Systems
Disc Drug Delivery using Nanotechnology
Disc Drug Designing
Disc Drug Development
Disc Drug Discovery
Disc Drug Interaction
Disc Drug Interactions
Disc Drug Metabolism
Disc Drug Safety Databases
Disc Drug Safety Information Maintenance
Disc Drug Safety Regulations
Disc Drug Therapy
Disc Drug Toxicology
Disc Drug drug interaction
Disc Drug food interaction
Disc Drugs metabolised by CYP2D6
Disc Europeon Drug Safety Regulations
Disc Expert Opinions on Drug Safety
Disc Fragment Based Drug Design
Disc Heat Shock Proteins
Disc Hepatic Metabolism of Drugs
Disc In Silico Methods
Disc Liver Drug Metabolism
Disc Medication Errors
Disc Molecular Modeling
Disc Nanomedicals
Disc Peptidomimetic
Disc Pharmaceutical Industry
Disc Pharmaceutical Toxicology
Disc Pharmacoepidemiological Studies
Disc Pharmacotherapy
Disc Phase I Drug Metabolism
Disc Phase II Drug Metabolism
Disc Pre-Clinical Drug Development
Disc Protease Substrate/Inhibitor
Disc Receptor Agonist/ Antagonist
Disc Reviews on Drug Safety
Disc Structure Based Drug Design
Disc UK Drug Safety Regulations
Disc US Drug Safety Regulations
Disc screening and Drug Design
 
Related Journals
Disc Drug Designing: Open Access
Disc Advances in Pharmacoepidemiology & Drug Safety
Disc Drug Designing: Open Access
Disc Drug Development & Research International Journal
Disc Drug Metabolism & Toxicology Journal
Disc Pharmaceutical Sciences & Emerging Drugs Journal
Disc Pharmaceutics & Drug Delivery Research Journal
 
Related Conferences
Disc Asia-Pacific Drug Formulation
July 11-13, 2016 Kuala Lumpur, Malaysia
Disc Conference on Nanomedicine
July 25-27, 2016 Bangkok, Thailand
Disc Conference on GMP GCP Quality Control
August 15-16, 2016 Toronto, Ontario, Canada
Disc Global Pharma Conference
August 22-24, 2016 New Orleans, Louisiana, USA
Disc Generic Drug Market
October 31 – November 2, 2016 Valencia, Spain
Disc Conference on Parenterals
November 07-08, 2016 Istanbul, Turkey
Disc Conference on Pharma Marketing
Nov 10-12, 2016 Alicante, Spain
Disc Polymer Chemistry Conference
November 14-16, 2016 Atlanta, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article

Post your comment

Name:
E-mail:
Your question:
Anti Spam Code:
  Reload  Can't read the image? click here to refresh

OMICS International Conferences 2016-17

Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
Conferences By Country
  USA   Spain   Poland
  Australia   Canada   Austria
  UAE   Switzerland   Turkey
  Italy   France   Finland
  Germany   India   Ukraine
  UK   Malaysia   Denmark
  Japan   Singapore   Mexico
  Brazil   South Africa   Norway
  South Korea   New Zealand   China
  Netherlands   Philippines
 
Medical & Clinical Conferences
Microbiology Oncology & Cancer
Diabetes & Endocrinology Cardiology
Nursing Dentistry
Healthcare Management Physical Therapy Rehabilitation
Neuroscience Psychiatry
Immunology Infectious Diseases
Gastroenterology Medical Ethics & Health Policies
Genetics & Molecular Biology Palliativecare
Pathology Reproductive Medicine & Women Healthcare
Alternative Healthcare Surgery
Pediatrics Radiology
Ophthalmology  
 
Conferences by Subject
Pharmaceutical Sciences
Pharma Marketing & Industry
Nutrition
Environmental Science
Physics & Materials Science
Environmental
EEE & Engineering
Veterinary
Chemical Engineering
Business Management
Massmedia
Geology & Earth science
 
 
©2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version